Skip to main content

Advertisement

SpringerLink
Log in

Matrix Metalloproteinases

Novel Targets for Directed Cancer Therapy

  • Review Article
  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Matrix metalloproteinases (MMPs), or matrixins, are a family of zinc endopeptidases that play a key role in both physiological and pathological tissue degradation. Normally, there is a careful balance between cell division, matrix synthesis and matrix degradation, which is under the control of cytokines, growth factors and cell matrix interactions. The MMPs are involved in remodelling during tissue morphogenesis and wound healing.

Under pathological conditions, this balance is altered: in arthritis, there is uncontrolled destruction of cartilage; in cancer, increased matrix turnover is thought to promote tumour cell invasion. The demonstration of a functional role of MMPs in arthritis and tumour metastasis raises the possibility of therapeutic intervention using synthetic MMP inhibitors with appropriate selectivity and pharmacokinetics. As the process of drug discovery focuses on structure-based design, efforts to resolve the 3-dimensional structures of the MMP family have intensified. Several novel MMP inhibitors have been identified and are currently being investigated in clinical trials. The structural information that is rapidly accumulating will be useful in refining the available inhibitors to selectively target specific MMP family members.

In this review, we focus on the role of MMPs and their inhibitors in tumour invasion, metastasis and angiogenesis, and examine how MMPs may be targeted to prevent cancer progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stetler-Stevenson WG, Brown PD, Onisto M, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933–8

    PubMed  CAS  Google Scholar 

  2. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389–96

    PubMed  CAS  Google Scholar 

  3. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654–9

    PubMed  CAS  Google Scholar 

  4. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996; 23: 1341–4

    PubMed  CAS  Google Scholar 

  5. Hollstein M, Soussi T, Thomas G, et al. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 1997; 143: 369–89

    PubMed  CAS  Google Scholar 

  6. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer [see comments]. J Urol 1997; 157: 569–74

    PubMed  CAS  Google Scholar 

  7. Vinante F, Vassanelli A, Zanotti R, et al. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders. Int J Clin Lab Res 1995; 25: 189–94

    PubMed  CAS  Google Scholar 

  8. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–64

    PubMed  CAS  Google Scholar 

  9. Zinzani PL, Baccini C, Zaccaria A, et al. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin’s lymphoma. Eur J Haematol 1996; 57: 335–40

    PubMed  CAS  Google Scholar 

  10. Liotta LA, Abe S, Robey PG, et al. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci U S A 1979; 76: 2268–72

    PubMed  CAS  Google Scholar 

  11. Drewa G, Zbytniewski Z, Kanclerz A. Activity of some lysosomal hydrolases in the homogenates of transplantable melanotic and amelanotic melanoma in golden hamster (Mesocricetus auratus, Waterhouse). Arch Geschwulstforsch 1978; 48: 198–201

    PubMed  CAS  Google Scholar 

  12. Poole AR, Tiltman KJ, Recklies AD, et al. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273: 545–7

    PubMed  CAS  Google Scholar 

  13. Stetler-Stevenson WG, Aznovoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541–73

    PubMed  CAS  Google Scholar 

  14. Shintani S, Alcalde RE, Matsumara T, et al. Extracellular matrices expression in invasion area of adenoid cystic carcinoma of salivary glands. Cancer Lett 1997; 116: 9–14

    PubMed  CAS  Google Scholar 

  15. Jaspars LH, Bonnet P, Bloemena E, et al. Extracellular matrix and beta 1 integrin expression in nodal and extranodal T-cell lymphomas. J Pathol 1996; 178: 36–43

    PubMed  CAS  Google Scholar 

  16. Liotta LA. Tumor invasion and metastases — role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46: 1–7

    PubMed  CAS  Google Scholar 

  17. Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188–94

    PubMed  CAS  Google Scholar 

  18. Corcoran ML, Kleiner DE, Stetler-Stevenson WG. Regulation of matrix metalloproteinases during extracellular matrix turnover. Adv Exp Med Biol 1995; 385: 151–9; discussion 179–84

    PubMed  CAS  Google Scholar 

  19. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer 1996; 73: 1401–8

    PubMed  CAS  Google Scholar 

  20. Seiki M. Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol 1996; 213: 23–32

    PubMed  CAS  Google Scholar 

  21. Costello PC, Del Maestro RF, Stetler-Stevenson WG. Gelatinase A expression in human malignant gliomas. Ann N Y Acad Sci 1994; 732: 450–2

    PubMed  CAS  Google Scholar 

  22. Emmert-Buck MR, Roth MJ, Zhuang Z, et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994; 145: 1285–90

    PubMed  CAS  Google Scholar 

  23. Grigioni WF, D’Errico A, Fiorentino M, et al. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn Mol Pathol 1994; 3: 163–9

    PubMed  CAS  Google Scholar 

  24. Polette M, Gilbert N, Stas I, et al. Gelatinase A expression and localization in human breast cancers: an in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994; 424: 641–5

    PubMed  CAS  Google Scholar 

  25. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062–72

    PubMed  CAS  Google Scholar 

  26. Stetler-Stevenson WG. Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994; 14: 259–68

    PubMed  CAS  Google Scholar 

  27. Cawston TE, Galloway WA, Mercer E, et al. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159–65

    PubMed  CAS  Google Scholar 

  28. Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996; 93: 7069–74

    PubMed  CAS  Google Scholar 

  29. Ochieng J, Fridman R, Nangia-Makker P, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994; 33: 14109–14

    PubMed  CAS  Google Scholar 

  30. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells [see comments]. Nature 1994; 370: 61–5

    PubMed  CAS  Google Scholar 

  31. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602–8

    PubMed  CAS  Google Scholar 

  32. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996; 56: 2707–10

    PubMed  CAS  Google Scholar 

  33. Kinoshita T, Sato H, Takino T, et al. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase Aby a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 1996; 56: 2535–8

    PubMed  CAS  Google Scholar 

  34. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578–82

    PubMed  Google Scholar 

  35. Libson AM, Gittis AG, Collier IE, et al. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A [letter]. Nat Struct Biol 1995; 2: 938–42

    PubMed  CAS  Google Scholar 

  36. Murphy G, Allan JA, Willenbrock F, et al. The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992; 267: 9612–8

    PubMed  CAS  Google Scholar 

  37. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995; 3: 527–30

    PubMed  CAS  Google Scholar 

  38. Murphy G, Nguyen Q, Cockett MI, et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994; 269: 6632–6

    PubMed  CAS  Google Scholar 

  39. Murphy G, Willenbrock F, Ward RV, et al. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases [published erratum appears in Biochem J 1992 Jun 15; 284 Pt 3: 935]. Biochem J 1992; 283: 637–41

    PubMed  CAS  Google Scholar 

  40. Strongin AY, Collier IE, Krasnov PA, et al. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 1993; 43: 158–62

    PubMed  CAS  Google Scholar 

  41. Ward RV, Atkinson SJ, Reynolds JJ, et al. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem J 1994; 304: 263–9

    PubMed  CAS  Google Scholar 

  42. Emmert-Buck MR, Emonard HP, Corcoran ML, et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995; 364: 28–32

    PubMed  CAS  Google Scholar 

  43. Kleiner DE, Unsworth EJ, Krutzsch HC, et al. Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry 1992; 31: 1665–72

    PubMed  CAS  Google Scholar 

  44. Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375–80

    PubMed  CAS  Google Scholar 

  45. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995; 270: 14313–8

    PubMed  CAS  Google Scholar 

  46. Murphy G, Houbrechts A, Cockett MI, et al. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity [published erratum appears in Biochemistry 1991 Oct 22; 30 (42): 10362]. Biochemistry 1991; 30: 8097–102

    PubMed  CAS  Google Scholar 

  47. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2: a new member of the OB fold protein family. Biochemistry 1994; 33: 11745–59

    PubMed  CAS  Google Scholar 

  48. Willenbrock F, Crabbe T, Slocombe PM, et al. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993; 32: 4330–7

    PubMed  CAS  Google Scholar 

  49. Ura H, Bonfil RD, Reich R, et al. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogenetransformed human bronchial epithelial cells. Cancer Res 1989; 49: 4615–21

    PubMed  CAS  Google Scholar 

  50. Thorgeirsson UP, Liotta LA, Kalebic T, et al. Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Natl Cancer Inst 1982; 69(5): 1049–54

    PubMed  CAS  Google Scholar 

  51. Schultz RM, Silberman S, Persky B, et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48(19): 5539–45

    PubMed  CAS  Google Scholar 

  52. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82(7): 589–95

    PubMed  CAS  Google Scholar 

  53. DeClerck YA, Yean TD, Chan D, et al. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51(8): 2151–7

    PubMed  CAS  Google Scholar 

  54. Albini A, Melchiori A, Santi L, et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83(11): 775–9

    PubMed  CAS  Google Scholar 

  55. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the over-expression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299–304

    PubMed  CAS  Google Scholar 

  56. Tsuchiya Y, Sato H, Endo Y, et al. Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 1993; 53: 1397–402

    PubMed  CAS  Google Scholar 

  57. Kawamata H, Kawai K, Kameyama S, et al. (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 1995; 63: 680–7

    PubMed  CAS  Google Scholar 

  58. Otani Y, Okazaki I, Arai M, et al. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 1994; 29: 391–7

    PubMed  CAS  Google Scholar 

  59. Gray ST, Yun K, Motoori T, et al. Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 1993; 143: 663–71

    PubMed  CAS  Google Scholar 

  60. Polette M, Clavel C, Muller D, et al. Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991; 11: 76–83

    PubMed  CAS  Google Scholar 

  61. Gray ST, Wilkins RJ, Yun K. Interstitial collagenase gene expression in oral squamous cell carcinoma. Am J Pathol 1992; 141: 301–6

    PubMed  CAS  Google Scholar 

  62. Wolf C, Chenard MP, Durand de Grossouvre P, et al. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992; 99: 870–2

    PubMed  CAS  Google Scholar 

  63. Pyke C, Ralfkiaer E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359–65

    PubMed  CAS  Google Scholar 

  64. Gress TM, Muller-Pillasch F, Lerch MM, et al. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407–13

    PubMed  CAS  Google Scholar 

  65. Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma: demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144: 585–91

    PubMed  CAS  Google Scholar 

  66. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365–9

    PubMed  CAS  Google Scholar 

  67. Pyke C, Ralfkiaer E, Huhtala P, et al. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992; 52: 1336–41

    PubMed  CAS  Google Scholar 

  68. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126–31

    PubMed  CAS  Google Scholar 

  69. Autio-Harmainen H, Karttunen T, Hurskainen T, et al. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312–21

    PubMed  CAS  Google Scholar 

  70. Canete-Soler R, Litzky L, Lubensky I, et al. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol 1994; 144: 518–27

    PubMed  CAS  Google Scholar 

  71. Nielsen BS, Timshel S, Kjeldsen L, et al. 92kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1995; 65: 57–62

    Google Scholar 

  72. Muller D, Wolf C, Abecassis J, et al. Increased stromelysin 3 gene squamous cell carcinomas. Cancer Res 1993; 53: 165–9

    PubMed  CAS  Google Scholar 

  73. Rouyer N, Wolf C, Chenard MP, et al. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1995; 14: 269–75

    CAS  Google Scholar 

  74. Newell KJ, Witty JP, Rodgers WH, et al. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994; 10: 199–206

    PubMed  CAS  Google Scholar 

  75. McDonnell S, Navre M, Coffey RJ, et al. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527–33

    PubMed  CAS  Google Scholar 

  76. Pajouh MS, Nagle RB, Breathnach R, et al. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117: 144–50

    PubMed  CAS  Google Scholar 

  77. Nomura H, Sato H, Seiki M, et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263–6

    PubMed  CAS  Google Scholar 

  78. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92: 2730–4

    PubMed  CAS  Google Scholar 

  79. Ohtani H, Motohashi H, Sato H, et al. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer 1996; 68: 565–70

    PubMed  CAS  Google Scholar 

  80. Noel A, Munaut C, Nusgens B, et al. Different mechanisms of extracellular matrix remodeling by fibroblasts in response to human mammary neoplastic cells. Invasion Metastasis 1993; 13: 72–81

    PubMed  CAS  Google Scholar 

  81. Noel AC, Polette M, Lewalle J-M, et al. Coordinate enhancement of gelatinase A mRNA and activity levels. Int J Cancer 1994; 56: 331–6

    PubMed  CAS  Google Scholar 

  82. Biswas C. Collagenase stimulation in cocultures of human fibroblasts and human tumor cells. Cancer Lett 1984; 24: 201–7

    PubMed  CAS  Google Scholar 

  83. Kataoka H, DeCastro R, Zucker S, et al. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993; 53: 3154–8

    PubMed  CAS  Google Scholar 

  84. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434–9

    PubMed  CAS  Google Scholar 

  85. Laiho M, Keski-Oja J. Growth factors in the regulation of peri-cellular proteolysis: a review. Cancer Res 1989; 49: 2533–53

    PubMed  CAS  Google Scholar 

  86. Van Der Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumours. Int J Cancer 1990; 45: 1071–8

    PubMed  Google Scholar 

  87. Murray GI, Duncan ME, O’Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461–2

    PubMed  CAS  Google Scholar 

  88. Daidone MG, Silvestrini R, D’Errico A, et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 1991; 48: 529–32

    PubMed  CAS  Google Scholar 

  89. Grigioni WF, Garbisa S, D’Errico A, et al. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 1991; 138: 647–54

    PubMed  CAS  Google Scholar 

  90. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548–9

    PubMed  CAS  Google Scholar 

  91. Brown PD, Bloxidge RE, Stuart NS, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574–8

    PubMed  CAS  Google Scholar 

  92. Brown PD, Bloxidge RE, Anderson E, et al. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993; 11: 183–9

    PubMed  CAS  Google Scholar 

  93. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325–9

    PubMed  CAS  Google Scholar 

  94. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51 (18 Suppl.): 5054S–9S

    PubMed  CAS  Google Scholar 

  95. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991; 9: 543–51

    PubMed  CAS  Google Scholar 

  96. Mignatti P, Tsuboi R, Robbins E, et al. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671–82

    PubMed  CAS  Google Scholar 

  97. Johnson MD, Kim HR, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160: 194–202

    PubMed  CAS  Google Scholar 

  98. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235–46

    PubMed  CAS  Google Scholar 

  99. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61

    PubMed  CAS  Google Scholar 

  100. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? [see comments]. Arthritis Rheum 1994; 37: 1115–26

    PubMed  CAS  Google Scholar 

  101. Karran EH, Young TJ, Markwell RE, et al. In vivo model of cartilage degradation — effects of a matrix metalloproteinase inhibitor. Ann Rheum Dis 1995; 54: 662–9

    PubMed  CAS  Google Scholar 

  102. Harper GP. Use of collagenase inhibitors in the treatment of demyelinating diseases. Eur Patent 1991; 423: 943

    Google Scholar 

  103. McMillan JI, Weeks R, West JW, et al. Pharmacological inhibition of gelatinase B induction and tumor cell invasion. Int J Cancer 1996; 67: 523–31

    PubMed  CAS  Google Scholar 

  104. Watson SA, Morris TM, Parsons SL, et al. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354–8

    PubMed  CAS  Google Scholar 

  105. Henderson B, Davies DE. The design of inhibitors of cartilage breakdown, osteoarthritis. In: Russell RGG, Dieppe PA, editors. Osteoarthritis: current research and prospects for pharmacological intervention. London: IBC Technical Services, 1991: 203–16

    Google Scholar 

  106. Brown PD. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann N Y Acad Sci 1994; 732: 217–21

    PubMed  CAS  Google Scholar 

  107. Darlak K, Moiller RB, Stack S, et al. Thiol-based inhibitors of mammalian collagenase. J Biol Chem 1990; 265: 5199–205

    PubMed  CAS  Google Scholar 

  108. Odake S, Morita Y, Morikawa T, et al. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem Biophys Res Commun 1994; 199: 1442–6

    PubMed  CAS  Google Scholar 

  109. Broadhurst MJ, Handa BK, Johnson WH, et al. Phosphinic acid derivatives. Eur Patent 1988; 276: 436

    Google Scholar 

  110. Hunter DJ, Marwell RE, Ward RW. Peptides with collagenase inhibiting activity. Eur Patent 1989; 320: 118

    Google Scholar 

  111. Markwell RE, Rahman SS, Ward RW. Phosphonopeptides with collagenase inhibiting activity. World Patent 1991; 91: 15506

    Google Scholar 

  112. Markwell RE, Ward RW, Ratcliffe SJ. Phosphonopeptides with collagenase inhibiting activity. World Patent 1991; 91: 15507

    Google Scholar 

  113. Roberts WH, Borkakoti NA, Johnson N. Collagenase inhibitors: their design and therapeutic use. J Enzyme Inhib 1987; 2: 1–22

    PubMed  Google Scholar 

  114. Seed M, Ismaiel S, Cheung CY, et al. Inhibition of interleukin 1 beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U2739. Ann Rheum Dis 1993; 52: 37–43

    PubMed  CAS  Google Scholar 

  115. Nixon J, Bottomley KM, Broadhurst MJ, et al. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React 1991; 3: 237–41

    Google Scholar 

  116. Andrews HJ, Plumpton TA, Harper GP, et al. A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro. Agents Actions 1992; 37: 147–54

    PubMed  CAS  Google Scholar 

  117. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2: a new member of the OB fold protein family. Biochemistry 1994; 33: 11745–59

    PubMed  CAS  Google Scholar 

  118. Dhanaraj V, Ye QZ, Johnson LL, et al. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996; 4: 375–86

    PubMed  CAS  Google Scholar 

  119. Van Doren SR, Kurochkin AV, Hu W, et al. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci 1995; 4: 2487–98

    PubMed  Google Scholar 

  120. Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994; 263: 375–7

    PubMed  CAS  Google Scholar 

  121. Gohlke U, Gomis-Ruth FX, Crabbe T, et al. The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett 1996; 378: 126–30

    PubMed  CAS  Google Scholar 

  122. Stams T, Spurlino JC, Smith DL, et al. Structure of human neutrophil collagenase reveals large S1’ specificity pocket. Nat Struct Biol 1994; 1: 119–23

    PubMed  CAS  Google Scholar 

  123. Gomis-Ruth FX, Grams F, Yiallouros I, et al. Crystal structures, spectroscopic features, and catalytic properties of cobalt(II), copper(II), nickel(II), and mercury(II) derivatives of the zinc endopeptidase astacin: a correlation of structure and proteolytic activity. J Biol Chem 1994; 269: 17111–7

    PubMed  CAS  Google Scholar 

  124. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815–22

    PubMed  CAS  Google Scholar 

  125. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293–8

    PubMed  CAS  Google Scholar 

  126. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629–33

    PubMed  CAS  Google Scholar 

  127. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726–8

    PubMed  CAS  Google Scholar 

  128. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460–4

    PubMed  CAS  Google Scholar 

  129. B Biotech/Tanabe pact on marimastat. Scrip 1996 Nov 22; 2183: 8

    Google Scholar 

  130. Naito K, Kanbayashi N, Nakajima S, et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 1994; 58: 730–5

    PubMed  CAS  Google Scholar 

  131. Tressler RJ, Wee J, Summers B, et al. Galardin, a potent metalloproteinase inhibitor, prolongs survival time in a B16-F10 melanoma experimental metastasis model [abstract]. Clin Exp Metastasis 1994; 12: 28

    Google Scholar 

  132. Anderson IC, Shipp MA, Docherty AJ, et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715–8

    CAS  Google Scholar 

  133. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, et al. The activation of human type IV collagenase proenzyme: sequence identification of the major conversion product following organomercurial activation. J Biol Chem 1989; 264: 1353–6

    PubMed  CAS  Google Scholar 

  134. Stetler-Stevenson WG, Talano JA, Gallagher ME, et al. Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment. Am J Med Sci 1991; 302: 163–70

    PubMed  CAS  Google Scholar 

  135. Melchiori A, Albini A, Ray JM, et al. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 1992; 52: 2353–6

    PubMed  CAS  Google Scholar 

  136. Benelli R, Adatia R, Ensoli B, et al. Inhibition of AIDS-Kaposi’s sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 1994; 6: 251–7

    PubMed  CAS  Google Scholar 

  137. Muir D. Metalloproteinase-dependent neurite outgrowth within a synthetic extracellular matrix is induced by nerve growth factor. Exp Cell Res 1994; 210: 243–52

    PubMed  CAS  Google Scholar 

  138. Ghosh SS. Dipeptide-analog-based metalloendopeptidase inhibitors and methods of using the same. World Patent 1991; 91: 05763

    Google Scholar 

  139. Ghosh SS, Mobashery S. N-acyl peptide metalloproteinase inhibitors and methods of using the same. World Patent 1991; 91: 05555

    Google Scholar 

  140. Wallace DA, Bates SRE, Walker B, et al. Competitive inhibition of human skin collagenase by N-benzyloxycarbonyl-L-pro-lyl-L-alanyl-3-amino-oxopropyl-L-leucyl-L-alanylglycine ethyl ester. Biochem J 1986; 239: 797–9

    PubMed  CAS  Google Scholar 

  141. Greenwald RA, Moak SA, Ramamurthy NS, et al. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and, in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992; 19: 927–38

    PubMed  CAS  Google Scholar 

  142. Bols M. Inhibition of collagenase by aranciamycin and aranciamycin derivatives. J Med Chem 1992; 35: 2768–71

    PubMed  CAS  Google Scholar 

  143. Golub LM, McNamara TF, D’Angelo G, et al. A non-bacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310–4

    PubMed  CAS  Google Scholar 

  144. Tanaka T, Metori K, Mineo S, et al. Studies on collagenase inhibitors: II. Inhibitory effects of anthraquinones on bacterial collagenase. J Pharm Soc Jpn 1990; 110: 688–92

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Anita E. Yu, Robert E. Hewitt, Edward W. Connor &  William G. Stetler-Stevenson (Chief)

Authors
  1. Anita E. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Hewitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward W. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William G. Stetler-Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William G. Stetler-Stevenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, A.E., Hewitt, R.E., Connor, E.W. et al. Matrix Metalloproteinases. Drugs & Aging 11, 229–244 (1997). https://doi.org/10.2165/00002512-199711030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711030-00006

Keywords

Search

Navigation